$2.62
-0.23 (-8.07%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SER is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 8.6 days to cover (settled 2026-07-31) · insider 90d: 5 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| SAD Study in Patients With Parkinson's Disease and Motor FluctuationsNCT07422675Incidence and Temporal Profile of Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: SER-252 (PEOZ-apomorphine) · Device: enFuse | PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease | 40 | 2027-01-31 | in 165 d | 2026-06-05 |
| A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214NCT02579473Safety - Adverse Events and Serious Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: SER-214 | Parkinson's Disease | 20 | 2023-12-31 | — | 2023-04-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19